Orexin-A vs GPE
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and GPE (Glycyl-L-prolyl-L-glutamic acid) — benefits, dosing, side effects, research data, and where to buy.
| Property | Orexin-A | GPE |
|---|---|---|
| Category | Cognitive Enhancement | Cognitive Enhancement |
| Full Name | Hypocretin-1 (Orexin-A) | Glycyl-L-prolyl-L-glutamic acid |
| Molecular Weight | 3562 Da | 301.30 Da |
| Half-Life | Minutes to <1 hour | minutes |
| Amino Acids | 33 | 3 |
| Typical Dose | Research-only; no validated human dose | 0.1-10 mg/kg preclinical |
| Route | Intracerebroventricular/Intranasal | Intranasal/Intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 25 |
| Research Status | Pre-clinical | Pre-clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
GPE Benefits
- ✓memory consolidation
- ✓neuroprotection
- ✓synaptic plasticity
- ✓learning support
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
GPE Dosing
intranasal or ICV research doses|0.1-10 mg/kg preclinical range|repeat daily or intermittent protocols
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
GPE Side Effects
- ⚠limited human safety data
- ⚠short half-life
- ⚠local irritation with nasal delivery
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
GPE
Preclinical studies suggest GPE can reduce neuronal damage and support plasticity-related pathways in the brain. Research interest centers on hippocampal function, which links it to learning and memory paradigms.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.